Kuznicki Law is investigating the proposed sale of VectivBio Holding AG (NasdaqGS: VECT) to Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD). Under the terms of the proposed transaction, shareholders of VectivBio will receive $17.00 in cash for each share of VectivBio that they own. Kuuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Please note that the merger is structured as a tender offer, such that time may be of the essence.